NCT02809222View on ClinicalTrials.gov

Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls

NACompletedINTERVENTIONAL
Enrollment

138

Participants

Timeline

Start Date

October 25, 2016

Primary Completion Date

March 3, 2020

Study Completion Date

March 1, 2021

Conditions
Myelodysplastic SyndromeSecondary Acute Myeloid Leukemia
Interventions
OTHER

Samples

Blood samples

OTHER

Quality of life questionnaire

Questionnaire to assess the quality of life of cancer patients

Trial Locations (2)

3704

Department of Haematology and Cell Therapy, University Hospital, Tours, Tours

37044

Clinical Research Center, University Hospital, Tours, Tours

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Tours Autogreffe

UNKNOWN

collaborator

Novartis

INDUSTRY

lead

University Hospital, Tours

OTHER

NCT02809222 - Plasmatic L-AScorbic Acid in MYelodyplastic Syndroms and Controls | Biotech Hunter | Biotech Hunter